scholarly journals Targeting trimeric transmembrane domain 5 of oncogenic latent membrane protein 1 using a computationally designed peptide

2019 ◽  
Vol 10 (32) ◽  
pp. 7584-7590 ◽  
Author(s):  
Yibo Wang ◽  
Yinghua Peng ◽  
Bo Zhang ◽  
Xiaozheng Zhang ◽  
Hongyuan Li ◽  
...  
Keyword(s):  
Membrane Protein ◽  
In Silico ◽  
Transmembrane Domain ◽  
Transmembrane Helix ◽  
Latent Membrane Protein ◽  
Peptide Inhibitor ◽  
Latent Membrane Protein 1

A peptide inhibitor was designed in silico and validated experimentally to disrupt homotrimeric transmembrane helix assembly.

scholarly journals Transmembrane Domains 1 and 2 of the Latent Membrane Protein 1 of Epstein-Barr Virus Contain a Lipid Raft Targeting Signal and Play a Critical Role in Cytostasis

2003 ◽  
Vol 77 (6) ◽  
pp. 3749-3758 ◽  
Author(s):  
William F. Coffin ◽  
Timothy R. Geiger ◽  
Jennifer M. Martin
Keyword(s):  
Membrane Protein ◽  
Signaling Pathways ◽  
Lipid Raft ◽  
Epstein Barr Virus ◽  
Transmembrane Domain ◽  
Latent Membrane Protein ◽  
Transmembrane Domains ◽  
Latent Membrane Protein 1 ◽  
Barr Virus ◽  
Epstein Barr

ABSTRACT The latent membrane protein 1 (LMP-1) oncoprotein of Epstein-Barr virus (EBV) is a constitutively active, CD40-like cell surface signaling protein essential for EBV-mediated human B-cell immortalization. Like ligand-activated CD40, LMP-1 activates NF-κB and Jun kinase signaling pathways via binding, as a constitutive oligomer, to tumor necrosis factor receptor-associated factors (TRAFs). LMP-1's lipid raft association and oligomerization have been linked to its activation of cell signaling pathways. Both oligomerization and lipid raft association require the function of LMP-1's polytopic multispanning transmembrane domain, a domain that is indispensable for LMP-1's growth-regulatory signaling activities. We have begun to address the sequence requirements of the polytopic hydrophobic transmembrane domain for LMP-1's signaling and biochemical activities. Here we report that transmembrane domains 1 and 2 are sufficient for LMP-1's lipid raft association and cytostatic activity. Transmembrane domains 1 and 2 support NF-κB activation, albeit less potently than does the entire polytopic transmembrane domain. Interestingly, LMP-1's first two transmembrane domains are not sufficient for oligomerization or TRAF binding. These results suggest that lipid raft association and oligomerization are mediated by distinct and separable activities of LMP-1's polytopic transmembrane domain. Additionally, lipid raft association, mediated by transmembrane domains 1 and 2, plays a significant role in LMP-1 activation, and LMP-1 can activate NF-κB via an oligomerization/TRAF binding-independent mechanism. To our knowledge, this is the first demonstration of an activity's being linked to individual membrane-spanning domains within LMP-1's polytopic transmembrane domain.

scholarly journals Sequence Variations of Epstein-Barr Virus-Encoded Small Noncoding RNA and Latent Membrane Protein 1 in Hematologic Tumors in Northern China

Intervirology ◽  
2021 ◽  
Vol 64 (2) ◽  
pp. 69-80
Author(s):  
Hai-Yu Wang ◽  
Lingling Sun ◽  
Ping Li ◽  
Wen Liu ◽  
Zhong-Guang Zhang ◽  
...  
Keyword(s):  
Membrane Protein ◽  
Nested Pcr ◽  
Noncoding Rna ◽  
Epstein Barr Virus ◽  
Northern China ◽  
Latent Membrane Protein ◽  
Latent Membrane Protein 1 ◽  
Small Noncoding Rna ◽  
Barr Virus ◽  
Epstein Barr

<b><i>Objective:</i></b> To investigate the relationship between hematologic tumors and Epstein-Barr virus (EBV)-encoded small noncoding RNA (EBER) variations as well as latent membrane protein 1 (LMP1) variations. <b><i>Methods:</i></b> Patients with leukemia and myelodysplastic syndrome (MDS) were selected as subjects. Genotypes 1/2 and genotypes F/f were analyzed using the nested PCR technology, while EBER and LMP1 subtypes were analyzed by the nested PCR and DNA sequencing. <b><i>Results:</i></b> Type 1 was more dominant than type 2, found in 59 out of 82 (72%) leukemia and in 31 out of 35 (88.6%) MDS, while type F was more prevalent than type f in leukemia (83/85, 97.6%) and MDS (29/31, 93.5%) samples. The distribution of EBV genotypes 1/2 was not significantly different among leukemia, MDS, and healthy donor groups, neither was that of EBV genotypes F/f. EB-6m prototype was the dominant subtype of EBER in leukemia and MDS (73.2% [30/41] and 83.3% [10/12], respectively). The frequency of EB-6m was lower than that of healthy people (96.7%, 89/92), and the difference was significant (<i>p</i> &#x3c; 0.05). China 1 subtype was the dominant subtype of LMP1 in leukemia and MDS (70% [28/40] and 90% [9/10], respectively), and there was no significant difference in the distribution of LMP1 subtypes among the 3 groups (<i>p</i> &#x3e; 0.05). <b><i>Conclusion:</i></b> The distribution of EBV 1/2, F/f, EBER, and LMP1 subtypes in leukemia and MDS was similar to that in the background population in Northern China, which means that these subtypes may be rather region-restricted but not associated with leukemia and MDS pathogenesis.

Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia

Cancer ◽  
2010 ◽  
Vol 116 (4) ◽  
pp. 880-887 ◽  
Author(s):  
Jeffrey J. Tarrand ◽  
Michael J. Keating ◽  
Apostolia M. Tsimberidou ◽  
Susan O'Brien ◽  
Rocco P. LaSala ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Membrane Protein ◽  
Epstein Barr Virus ◽  
Significant Proportion ◽  
Latent Membrane Protein ◽  
Lymphocytic Leukemia ◽  
Latent Membrane Protein 1 ◽  
Barr Virus ◽  
Epstein Barr ◽  
Virus Latent Membrane Protein
Sign in / Sign up

Export Citation Format

Share Document